Newsfeeds - Spark Newswire

4 minute read

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow

Today, 10:52 PM

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.

ABCL

1 minute read

BioMarin Sells Priority Review Voucher For $110M

By Vandana Singh

Today, 10:52 PM

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)

BMRN

2 minute read

BioMarin Sells Rare Pediatric Disease Priority Review Voucher For $110M

By Bill Haddad

Today, 10:52 PM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained in

BMRN

4 minute read

BioMarin Announces Oral Presentation Of 2-Year Analysis Of Largest Phase 3 Gene Therapy Study In Adults With Severe Hemophilia A At 15th Annual Congress Of European Association For Haemophilia And Allied Disorders From Feb. 2-4

By Benzinga Newsdesk

Today, 10:52 PM

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study and an overall safety update of valoctocogene roxaparvovec, an

BMRN

1 minute read

BioMarin’s Hemophilia Gene Therapy Meets Efficacy Endpoints At Two Year Analysis

By Vandana Singh

Today, 10:52 PM

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) announced results from its ongoing Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.

BMRN

1 minute read

FDA
News

BioMarin Granted FDA Orphan Designation For Treatment Of Hereditary Angioedema

By Benzinga Newsdesk

Today, 10:52 PM

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=852221

BMRN

2 minute read

This Favorable Sign Appears On Biomarin Pharmaceutical’s Chart

By Benzinga Insights

Today, 10:52 PM

If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

BMRN